-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

5 Efficacy and Safety of Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib in Adults with Previously Treated Immune Thrombocytopenia (ITP): A Phase 3, Placebo-Controlled, Parallel-Group, Multicenter Study (LUNA 3)

Program: Marquee Sessions
Session: Plenary Scientific Session
Hematology Disease Topics & Pathways:
Research, Clinical trials, Bleeding and Clotting, Autoimmune disorders, Clinical Research, Diseases, Thrombocytopenias, Immune Disorders
Sunday, December 8, 2024, 2:00 PM-4:00 PM

David J Kuter, MD, DPhil1, Waleed Ghanima, MD, PhD2, Nichola Cooper, MD3*, Howard A. Liebman, MD, MA4, Lei Zhang5, Yu Hu6*, Yoshitaka Miyakawa, MD7*, Luisa Elena Morales Galindo8*, Ana Lisa Basquiera, MD, PhD9, Chuen Wen Tan, MBBCh BAO, FRCPath (UK)10*, Güray Saydam, MD11*, Marie Luise Hütter-Krönke, MD12*, Chatree Chai-Adisaksopha, M.D., Ph.D.13*, David Gomez-Almaguer, MD14, Huy Tran, FRACP, FRCPA, MBBS15*, Ho-Jin Shin, MD16*, Maria Cristina Pascual Izquierdo, MD, PhD17*, Ilya Kirgner, MD18*, Elisa Lucchini19*, Ganna Kuzmina20*, Sylvain Audia21*, Matias Cordoba, MD22*, Remco Diab23*, Mengjie Yao24*, Michelle J. Lee, MD, PhD25 and Ahmed Daak, MD, PhD, MSc, DPM/MFPM25

1Hematology Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA
2Østfold Hospital Trust, Grålum, Norway and Institute of Clinical Medicine, University of Oslo, Oslo, Norway
3Hammersmith Hospital, London, United Kingdom
4University of Southern California, Los Angeles, CA
5Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
6Wuhan Xie'he Hospital, Wuhan, China
7Department of Hematology, Saitama Medical University, Saitama, Japan
8IC La Serena Research SpA, La Serena, Chile
9Hospital Privado Universitario de Córdoba-Instituto Universitario de Ciencias Biomédicas de Córdoba (IUCBC), Cordoba, Argentina
10Department of Hematology, Singapore General Hospital, Singapore, Singapore
11Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Ege University, Izmir, Turkey
12Department of Hematology, Oncology and Tumorimmunology, Charité - Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany
13Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand
14Hospital Universitario Dr. José Eleuterio González. Facultad de Medicina, Universidad Autónoma de Nuevo León, Monterrey, Mexico
15Peninsula Private Hospital, Frankston, AUS
16Division of Hematology-Oncology, Department of Internal Medicine, Biochemical Research Institution, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea, Republic of (South)
17Instituto de Investigación Gregorio Marañon, Madrid, Spain
18Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
19UCO Ematologia, Azienda Sanitaria Universitaria Giuliano-Isontina, Trieste, Italy
20Municipal Enterprise Kryvyi Rih City Clinical Hospital #2 of Kryvyi Rih City Council, SI Dnipropetrovsk Medical Academy under the Ministry of Health of Ukraine, Kryvyi Rih, Ukraine
21CHU Dijon Bourgogne - Hopital Francois Mitterrand, Dijon, France
22Global Medical, Sanofi, Cambridge, MA
23Sanofi, Rotkreuz, Zug, Switzerland
24Sanofi, Bridgewater, NJ
25Sanofi, Cambridge, MA

Introduction: Patients with primary ITP who are not sufficiently responsive or intolerant to available therapies experience higher rates of morbidity, mortality, and impaired quality of life (QoL). Phase 2 results with covalent, reversible BTKi rilzabrutinib in ITP showed rapid and durable platelet responses with favorable safety.

Methods: The phase 3 LUNA 3 study enrolled adults ≥18 y and pediatrics 10-<18 y with primary persistent/chronic ITP and platelet counts <30×109/L within 2 wk of study initiation (NCT04562766; 2020-002063-60). Patients had response (platelet count ≥50×109/L) to previous IVIg/anti-D or corticosteroids (CS) that was not sustained and documented as intolerance, insufficient response, or any contraindication to any standard-of-care ITP therapy. Patients were stratified by splenectomy status (yes/no) and thrombocytopenia severity (averaged platelet counts <15×109/L or ≥15×109/L) and randomized 2:1 to oral rilzabrutinib 400 mg bid or placebo for up to 24 wk (double-blind), followed by rilzabrutinib only in the 28-wk open-label period (+4-wk safety follow-up) or long-term extension, if eligible. After the initial 12 wk, non-responders could join the open-label part or discontinue. Stable baseline doses of concomitant CS and/or TPO-RA, and rescue medication use were permitted. The primary endpoint was durable platelet response: platelet counts ≥50×109/L for ≥8 of the last 12 wk of the 24 wk blinded period without rescue therapy. This is the first report of efficacy and safety of the adult population.

Results: As of March 14, 2024, 202 randomized adults (n=133 rilzabrutinib, n=69 placebo) had a similar overall median baseline age of 47 y (range, 18-80), median baseline platelet count of 15×109/L, and 46% received ≥5 prior ITP therapies (including 28% splenectomized in both arms). Median duration of ITP was longer for rilzabrutinib-treated patients at 8.1 y (range, 0.3-52.2) vs placebo at 6.2 y (range, 0.3-35.8).

Platelet response (ie, responders: ≥50×109/L or ≥30–<50×109/L and doubled from baseline) was achieved in 86 (65%) rilzabrutinib vs 23 (33%) placebo patients. The primary endpoint of durable response was met in 31 (23%) rilzabrutinib vs 0 placebo patients (P<0.0001). For double-blind and open-label periods combined, durable response was met in 38/133 (29%) rilzabrutinib-randomized patients. Significant improvements with rilzabrutinib over placebo were seen in all secondary efficacy endpoints. Median time to first platelet count ≥50×109/L or ≥30–<50×109/L and ≥doubled from baseline was 36 d (95% CI, 22-44) for rilzabrutinib vs not achieved for placebo (HR=3.1 [95%, 1.9-4.9]; P<0.0001). Among patients who randomized to rilzabrutinib and achieved response, median time to first platelet response was 15 d (range, 2-99). Rilzabrutinib significantly reduced the need for rescue therapy by 52% vs placebo (P=0.0007). Significant and clinically meaningful improvements were observed with rilzabrutinib vs placebo, respectively, in physical fatigue (ITP-PAQ item 10) with a mean change (SE) from baseline at week 13 of 7.95 (2.13) vs –0.13 (2.86; P=0.01), and bleeding (per IBLS) with a mean change (SE) from baseline at week 25 of –0.04 (0.02) vs 0.05 (0.02; P=0.0006).

During the double-blind part, rilzabrutinib and placebo patients received treatment for a median of 98 days (range, 22-182) and 84 days (range, 17-173), respectively, with a median compliance rate of ≥98% for both. A similar percentage of rilzabrutinib and placebo patients had all-cause, any-grade adverse events (AEs) and serious AEs (SAEs); grade ≥2 GI AEs were comparable at 6% vs 4%. The most common treatment-related AEs for rilzabrutinib vs placebo were diarrhea (23% vs 4%), nausea (17% vs 6%), headache (8% vs 1%), and abdominal pain (6% vs 1%), all grade 1 or 2. All other related AEs were ≤5%. In the rilzabrutinib arm, 1 patient with multiple risk-factors had a treatment-related grade 3 peripheral embolism (SAE) and 1 patient died due to pneumonia unrelated to treatment.

Conclusion: Pivotal LUNA 3 phase 3 study results in patients with ITP showed that first-in-class BTKi rilzabrutinib has a robust therapeutic effect as shown by rapid and durable platelet response, reduced bleeding and need for rescue therapy, improved physical fatigue and QoL, and favorable safety and tolerability.

Disclosures: Kuter: Inmagenebio: Consultancy; Ligand: Consultancy; Medscape: Consultancy; Merck Sharp Dohme: Consultancy; New York Blood Center: Consultancy; Peerview: Consultancy; PER: Consultancy; Pfizer: Consultancy; Platelet Disorder Support Association: Consultancy; Regeneron: Consultancy; Seismic: Consultancy; Sobi: Consultancy; Takeda: Consultancy, Research Funding; UCB: Consultancy, Research Funding; Up-To-Date: Consultancy; Verve: Consultancy; AIRx: Consultancy; CRICO: Consultancy; Daiichi Sankyo: Consultancy; Dianthus: Consultancy; Electra Therapeutics: Consultancy; Fuji: Consultancy; Hemopure: Consultancy; Incyte: Consultancy; Immunovant: Consultancy; Hengrui: Consultancy; Chugai: Consultancy; Cellphire: Consultancy; Cellularity: Consultancy; Caremark: Consultancy; Bristol Myers Squibb: Consultancy; Argenx: Consultancy; Apellis: Consultancy; Amgen: Consultancy; Alpine: Consultancy; Alnylam: Consultancy, Research Funding; Alexion: Consultancy; Sanofi: Consultancy, Research Funding; Rigel: Consultancy, Research Funding; Principia: Consultancy, Research Funding; Novartis: Consultancy, Research Funding; Hutchmed: Consultancy, Research Funding; Biocryst: Consultancy, Research Funding; Kezar: Consultancy; Kyowa-Kirin: Consultancy; Momenta: Consultancy; Nuvig: Consultancy; Platelet Biogenesis: Consultancy; Protagonist: Consultancy; Zafgen: Consultancy. Ghanima: Grifols: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria, Research Funding; SOBI: Consultancy, Honoraria, Research Funding, Speakers Bureau; UCB: Consultancy; Argenx: Consultancy; Cellphire: Consultancy; Alpine: Consultancy; Kedrion: Consultancy; HiBio: Consultancy; HUTCHMED: Consultancy; Takeda: Consultancy; Bristol Myers Squibb: Honoraria; Bayer: Honoraria; Amgen: Consultancy, Honoraria; Hutchmed: Consultancy, Honoraria; Argenx: Consultancy, Honoraria; Alpine: Consultancy; Kedrion: Consultancy; Pfizer: Consultancy; Principia Biopharma Inc- a Sanofi Company: Consultancy. Cooper: Griffols: Consultancy, Honoraria; Novartis: Consultancy, Honoraria, Research Funding; Argenx: Consultancy, Honoraria; Rigel: Honoraria, Research Funding; Sobi: Consultancy, Honoraria; Amgen: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria. Liebman: University Southern California- Keck School of Medicine: Current Employment; Novartis: Consultancy; Sanofi: Consultancy, Research Funding; Alpine: Consultancy; Momenta: Research Funding. Miyakawa: Alexion: Research Funding; BioMarin: Research Funding; Chugai: Research Funding; CSL Behring: Research Funding; Janssen: Research Funding; Novartis: Membership on an entity's Board of Directors or advisory committees, Research Funding; Novo Nordisc: Research Funding; Pfizer: Research Funding; Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Asahi Kasei: Honoraria; Zenyaku: Consultancy; UCB: Consultancy, Research Funding; argenx: Consultancy, Honoraria. Basquiera: Amgen: Honoraria; Bristol: Honoraria; Servier: Honoraria; Pfizer: Honoraria; Janssen: Honoraria. Saydam: MSD: Research Funding. Hütter-Krönke: University Hospital Charité- Universitätsmedizin Berlin: Current Employment; Amgen: Honoraria; Sanofi: Honoraria; Jazz Pharmaceuticals: Honoraria; SOBI: Honoraria. Gomez-Almaguer: Astex Pharmaceuticals: Research Funding; Incyte: Research Funding; Seattle Genetics: Research Funding; AbbVie: Research Funding, Speakers Bureau; Gilead/Forty Seven: Research Funding; Kartos Therapeutics: Research Funding; Roche: Speakers Bureau; Sanofi: Speakers Bureau; Blueprint Medicines: Research Funding; Tevas: Speakers Bureau; ConstellationPharmaceuticals: Research Funding; BMS: Consultancy, Other: Advisory board, Speakers Bureau; Takeda: Consultancy, Other: Advisory board, Research Funding, Speakers Bureau; Novartis: Consultancy, Other: Advisory board, Speakers Bureau; Janssen: Consultancy, Other: Advisory board, Speakers Bureau; Amgen: Consultancy, Other: Advisory board, Research Funding, Speakers Bureau. Lucchini: Azienda Sanitaria Universitaria Giuliano-Isontina: Current Employment. Audia: Sanofi: Honoraria; Argenx: Honoraria; Novartis: Honoraria; Amgen: Honoraria. Cordoba: Sanofi: Current Employment, Current holder of stock options in a privately-held company. Diab: Sanofi: Current Employment, Other: Stocks. Lee: NCI: Other: This work was supported by the Hawaii Tumor Registry of the Univ of Hawaii Cancer Center through NCI SEER Contract Award HHSN261201300009I. The content is solely the responsibility of the authors. Does not necessarily represent the official views of NCI.. Daak: Sanofi: Current Employment, Current equity holder in publicly-traded company.

OffLabel Disclosure: Yes, it is off label. Rilzabrutinib is an investigational therapy being evaluated in a clinical study for the treatment of patients with immune thrombocytopenia.

See more of: Plenary Scientific Session
See more of: Marquee Sessions